Drug combinations for use in the treatment of cancer
A drug combination of TLR ligands, anti-CD40 antibodies, and glutamine metabolism inhibitors effectively targets and eliminates solid tumors by activating immune responses, offering complete tumor elimination and long-term immunity.
Patent Information
- Application Number
- JP2024528499
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-15
- Filing Date
- 2022-11-03
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, particularly for solid tumors like pancreatic adenocarcinoma, face challenges in effectively eliminating large tumors and metastases due to complex tumor immune resistance mechanisms, with checkpoint inhibitors being only partially effective and other therapies suppressing the immune system.
A drug combination comprising TLR ligands, anti-CD40 antibodies, and glutamine metabolism inhibitors, such as resiquimod, polyinosinic acid:polycytidylic acid, lipoteichoic acid, mannan-BAM, and 6-diazo-5-oxo-norleucine, is administered to activate innate and adaptive immunity and inhibit tumor growth.
The combination therapy can completely eliminate aggressive subcutaneous tumors and provide long-term immunological memory, showing synergistic effects in suppressing tumor growth and prolonging survival even in advanced cancer models.
Smart Images

Figure 2024541368000001 
Figure 2024541368000002 
Figure 2024541368000003
Abstract
Description
[Technical field]
[0001] The present invention relates to drug combinations and their use for the treatment of cancer, in particular for the treatment of solid tumors. [Background technology]
[0002] Tumor immune resistance is a highly complex process that consists of multiple, usually independent, intracellular and microenvironmental mechanisms. One example of a highly immune-resistant tumor is pancreatic adenocarcinoma, which has a unique tumor microenvironment with a dense stroma, low mutational load, and immunosuppressive mechanisms. The stromal environment forms an important biophysical barrier to immune and other cells, contributing to the aggressiveness of the disease and enhanced drug resistance. The low mutational load and immunosuppressive microenvironment hinder tumor cell recognition and suppress antitumor immunity. Thus, the poor clinical outcomes urge the development of new innovative therapeutic approaches to bring hope to patients with this diagnosis.
[0003] Currently, we are witnessing significant progress in the field of cancer immunotherapy. The most studied area is the use of checkpoint inhibitors. Also, attention is focused on the use of CAR-T lymphocytes. In the field of checkpoint inhibitors, the focus is shifting from anti-CTLA-4 antibodies to PD-1 / PD-L1 interventions and the combination of checkpoint inhibitors with other immune, chemo, and radiotherapy. However, the use of checkpoint inhibitors is effective in only about 20% of patients with a limited number of diagnoses. The main reason for the low efficacy of checkpoint inhibitors is that the defense of tumors against immune attacks is very complex and consists of several mostly independent mechanisms. Checkpoint inhibitors and CAR-T solve only part of the problem of this mosaic.
[0004] In a previous study, the inventors developed an immunotherapy composition containing a TLR (Toll-like receptor) ligand and a compound that marks tumor cells as targets for innate immune cell attack. This therapeutic mixture has shown good results in the treatment of melanoma (Non-Patent Documents 1 and 2). In the treatment of pancreatic adenocarcinoma and pheochromocytoma, which are very difficult to treat, it has been found that adding an anti-CD40 antibody, an agent that promotes both innate and adaptive immunity, to the therapeutic mixture is highly beneficial (Non-Patent Document 3).
[0005] Although this immunotherapy is highly effective, it has certain limitations and drawbacks: it is difficult or impossible to completely eliminate large tumors or large metastases with this treatment, therefore, further improvements in this immunotherapy are needed.
[0006] In an effort to improve on known immunotherapies, researchers have sought other therapies that would work in tandem with and support the immune system. Finding a suitable treatment has been extremely difficult, as many treatment options, such as chemotherapy and radiation therapy, suppress the immune system and would be counterproductive when used in combination with immunotherapies that boost the function of natural immunity.
[0007] It is an object of the present invention to develop a drug combination for use in the treatment of cancer which, when used therapeutically, can completely eliminate aggressive subcutaneous tumors and also results in long-term immune memory. [Prior art documents] [Non-patent literature]
[0008] [Non-Patent Document 1] Caisova V, Vieru A, Kumzakova Z et al., Innate immunity-based cancer immunotherapy:B16-F10 murine melanoma model, BMC Cancer, p.1-11, 2016 [Non-Patent Document 2] Caisova V, Uher O, Nedbalova P et al., Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis, Int Immunopharmacol.,p.86-96,2018 [Non-Patent Document 3] Caisova V,Li L,Gupta G et al.,The significant reduction or complete eradication of subcutaneous and metastatic lesions in a pheochromocytoma mouse model after immunotherapy using mannan-BAM,TLR ligands,and-anti-CD40,Cancers,p.1-21,2019 [Non-Patent Document 4] Janotova T, Jalovecka M, Auerova et al., The use of anchored agonists of phagocytic receptors for cancer immunotherapy:B16-F10 murine melanoma model,PLoS ONE,p.1-14,2014 [Non-Patent Document 5] Caisova V, Uher O, Nedbalova P et al.,Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis,Int Immunopharmacol.,p.86-96,2018 Summary of the Invention [Means for solving the problem]
[0009] The object of the present invention is achieved by the development of a drug combination for use in the treatment of cancer with active substances for immunotherapy, said combination comprising at least one TLR (Toll-like receptor) ligand, at least one compound that marks tumor cells as targets for immune cell attack, and at least one anti-CD40 antibody, and further comprising at least one inhibitor of glutamine metabolism. These active substances can be administered simultaneously or sequentially. Glutamine is very important for tumor growth and is generally consumed in large amounts by tumors. Glutamine is used for the generation of energy and serves as a nitrogen source in the synthesis of nucleic acids and some amino acids. It is also involved in the regulation of cellular redox homeostasis. Glutamate produced from glutamine by glutaminase activity is further metabolized to α-ketoglutarate, which serves as a carbon source for the very important cycle of tricarboxylic acids.
[0010] TLR ligands are substances involved in the infiltration of tumors by innate immune cells and their activation. Furthermore, TLR ligands contribute to the formation of a Th1 antitumor environment and promote the formation of costimulatory molecules. Thus, TLR ligands promote efficient antigen presentation and engagement of adaptive immunity. In a preferred embodiment, the TLR ligand is a substance selected from the group comprising resiquimod (R-848), polyinosinic:polycytidylic acid (poly(I:C)) in free acid form or salt form, lipoteichoic acid (LTA) in free acid form or salt form, more preferably a combination of at least two of these substances. In the present specification, acid salt refers to a salt of an acid with a pharma- ceutically acceptable cation, in particular an alkali metal cation, an alkaline earth metal cation, and an ammonium cation.
[0011] In a preferred embodiment, the compound that marks tumor cells as targets for innate immune cell attack is mainly the ligand of phagocyte receptors, such as Dectin-1, MR, MBL, CR3, CR4 receptors, and the ligand of scavenger receptors SR-A1, SR-A2, and MARCO.The compound that marks tumor cells as targets for innate immune cell attack is preferably a mannan-biocompatible membrane anchor (mannan-BAM) complex.These compounds bind to tumor cells and mark them as targets for innate immune cell attack.Innate immune cells include neutrophils, monocytes, macrophages, dendritic cells, and NK cells.
[0012] Anti-CD40 antibodies promote both innate and adaptive immunity.
[0013] In a preferred embodiment, the glutamine metabolism inhibitor is selected from the group comprising azaserine, 6-diazo-5-oxo-norleucine referred to as DON, 5-diazo-4-oxo-L-norvaline referred to as L-DONV, acivicin, azotomycin, bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide referred to as BPTES, ebselen, chererythrine, apomorphine, 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido(pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide referred to as CB-839. These substances may be administered in the form of a prodrug. The prodrug reacts in vivo to form the active substance. As used herein, the prodrug is also included in the term "glutamine metabolism inhibitor."
[0014] Preferably, the present invention provides a pharmaceutical combination comprising resiquimod, polyinosinic:polycytidylic acid in free acid or salt form, lipoteichoic acid in free acid or salt form, mannan-BAM, an anti-CD40 antibody, and at least one glutamine metabolism inhibitor.
[0015] In a preferred embodiment, the present invention provides a pharmaceutical combination comprising resiquimod, polyinosinic:polycytidylic acid in free acid or salt form, lipoteichoic acid in free acid or salt form, mannan-BAM, an anti-CD40 antibody, and 6-diazo-5-oxo-norleucine, or a prodrug thereof.
[0016] In a preferred embodiment, the drug combination is administered intraperitoneally, subcutaneously, or intratumorally into the tissue in which the tumor resides.
[0017] The objects of the present invention are further achieved by the use of a pharmaceutical composition for the treatment of cancer, in particular for the treatment of solid tumors, most preferably for the treatment of pancreatic adenocarcinoma, comprising the step of administering to a human or animal subject in need of such treatment a pharmaceutical combination of active substances for immunotherapy comprising at least one TLR (Toll-like receptor) ligand, at least one compound which labels tumor cells as targets for immune cell attack, at least one anti-CD40 antibody, and further at least one inhibitor of glutamine metabolism.
[0018] In a preferred embodiment, a pharmaceutical combination of active agents consisting of resiquimod, polyinosinic:polycytidylic acid, lipoteichoic acid, mannan-BAM and anti-CD40 antibody is administered intratumorally and 6-diazo-5-oxo-L-norleucine is administered intratumorally or systemically prior to the combination.
[0019] In a preferred embodiment, a pharmaceutical combination of active substances for immunotherapy comprising at least one TLR (Toll-like receptor) ligand, at least one compound that labels tumor cells as a target for immune cell attack, and at least one anti-CD40 antibody is administered intratumorally, followed by administration of at least one glutamine metabolism inhibitor.
[0020] In a preferred embodiment, a pharmaceutical combination of active agents consisting of resiquimod, polyinosinic:polycytidylic acid, lipoteichoic acid, mannan-BAM and anti-CD40 antibody is administered intratumorally, followed by intratumoral or systemic administration of 6-diazo-5-oxo-L-norleucine.
[0021] In a preferred embodiment, a pharmaceutical combination of active substances for immunotherapy comprising at least one TLR ligand, at least one compound that labels tumor cells as targets for immune cell attack, at least one anti-CD40 antibody, and at least one glutamine metabolism inhibitor are administered simultaneously.
[0022] In a preferred embodiment, a pharmaceutical combination of active agents consisting of resiquimod, polyinosinic:polycytidylic acid, lipoteichoic acid, mannan-BAM, and anti-CD40 antibody is administered intratumorally, with concomitant administration of 6-diazo-5-oxo-L-norleucine intratumorally or systemically.
[0023] The substances used in the present invention are commercially available. Although the individual substances or partial combinations thereof are already known in the art, it has now surprisingly been found that the combination of these active substances, i.e. immunometabolic therapy based on the involvement of corresponding mechanisms of action, produces a synergistic effect, stopping or reducing tumor growth and prolonging survival even in large aggressive solid tumors.
[0024] The advantage of this drug combination for use in the treatment of cancer is that it can completely eliminate aggressive subcutaneous tumors when used therapeutically, and also results in long-term immune memory.
[0025] The present invention will be described in detail below with reference to the accompanying drawings. [Brief description of the drawings]
[0026] [Figure 1A] 1A-1C show the results of immunometabolic treatment of mice with pancreatic adenocarcinoma using drug combinations, with FIG. 1A showing inhibition of tumor growth. [Figure 1B] 1A-1C show the results of immunometabolic treatment of mice with pancreatic adenocarcinoma using drug combinations, with FIG. 1B showing inhibition of tumor growth. [Figure 1C] 1A-1C show the results of immunometabolic treatment of mice with pancreatic adenocarcinoma using a drug combination, with FIG. 1C showing increased survival of the mice. [Figure 2A] 2A and 2B show the results of immunometabolic treatment of mice with highly advanced pancreatic adenocarcinoma using the drug combination, with FIG. 2A showing inhibition of tumor growth. [Figure 2B] Figures 2A and 2B show the results of immunometabolic treatment of mice with highly advanced pancreatic adenocarcinoma using a drug combination, with Figure 2B showing extended survival of the mice. [Figure 3A] 3A and 3B show the results of immunometabolic treatment of mice with pancreatic adenocarcinoma using a drug combination, with FIG. 3A showing inhibition of tumor growth. [Figure 3B] Figures 3A and 3B show the results of immunometabolic treatment of mice with pancreatic adenocarcinoma using a drug combination, with Figure 3B showing increased survival of the mice. [Figure 4A] 4A-4C show the results of using a drug combination of intratumoral MBTA therapy and ip administration of a glutamine antagonist (DON) at two time points in a bilateral Panc02 model, with FIG. 4A showing inhibition of tumor growth. [Figure 4B] 4A-4C show the results of using a drug combination of intratumoral MBTA therapy and ip administration of a glutamine antagonist (DON) at two time points in a bilateral Panc02 model, and FIG. 4B shows the inhibition of tumor growth. [Figure 4C] Figures 4A-4C show the results of using a drug combination of intratumoral MBTA therapy and ip administration of a glutamine antagonist (DON) at two time points in a bilateral Panc02 model, and Figure 4C shows the extension of mouse survival time. [Figure 5A]5A-5C show the results of sc administration of DON at different doses in a bilateral Panc02 model, with FIG. 5A showing inhibition of tumor growth. [Figure 5B] 5A-5C show the results of sc administration of DON at different doses in a bilateral Panc02 model, and FIG. 5B shows the inhibition of tumor growth. [Figure 5C] 5A-5C show the results of sc administration of DON at different doses in a bilateral Panc02 model, and FIG. 5C shows the prolongation of mouse survival. [Figure 6A] 6A-6C show the results of a comparison of it and ip administration of DON in a bilateral Panc02 model, with FIG. 6A showing inhibition of tumor growth. [Figure 6B] 6A-6C show the results of it vs. ip administration of DON in a bilateral Panc02 model, and FIG. 6B shows the inhibition of tumor growth. [Figure 6C] 6A-6C show the results of it versus ip administration of DON in a bilateral Panc02 model, with FIG. 6C showing the increased survival time of mice. [Figure 7A] 7A to 7F show the results (assessment of side effects) of a combination of MBTA immunotherapy and inhibition of glutamine metabolism by DON in a bilateral Panc02 model, with FIG. 7A showing inhibition of tumor growth. [Figure 7B] 7A-7F show the results (assessment of side effects) of a combination of MBTA immunotherapy and inhibition of glutamine metabolism with DON in a bilateral Panc02 model, and FIG. 7B shows the inhibition of tumor growth. [Figure 7C] 7A to 7F show the results (evaluation of side effects) of a combination of MBTA immunotherapy and inhibition of glutamine metabolism by DON in a bilateral Panc02 model, and FIG. 7C shows the extension of mouse survival time. [Figure 7D] 7A to 7F show the results (evaluation of side effects) of a combination of MBTA immunotherapy and inhibition of glutamine metabolism by DON in a bilateral Panc02 model, and FIG. 7D shows food intake. [Figure 7E] 7A to 7F show the results (evaluation of side effects) of a combination of MBTA immunotherapy and inhibition of glutamine metabolism by DON in a bilateral Panc02 model, and FIG. 7E shows water intake. [Figure 7F] 7A to 7F show the results (evaluation of side effects) of a combination of MBTA immunotherapy and inhibition of glutamine metabolism by DON in a bilateral Panc02 model, and FIG. 7F shows the body weight of the mice. [Figure 8] Shows the effect of DON on immune cell infiltration in left-sided MBTA-untreated parallel pancreatic adenocarcinoma tumors (bilateral Panc02 model). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] Drug Combinations The drug combination described below for testing its activity in the treatment of cancer, particularly in the treatment of solid tumors such as pancreatic adenocarcinoma, contained two TLR ligands, polyinosinic:polycytidylic acid (poly(I:C)) and lipoteichoic acid in sodium salt form, an anti-CD40 antibody, one compound that labels tumor cells in the form of mannan-BAM, and one glutamine metabolism inhibitor in the form of 6-diazo-5-oxo-norleucine, or called DON. In another non-illustrated embodiment, the drug combination consists of at least one, preferably at least two TLR ligands selected from the group of resiquimod, polyinosinic:polycytidylic acid in acid or salt form, and lipoteichoic acid in acid or salt form. In another non-illustrated embodiment, the drug combination consists of at least one compound that labels tumor cells, selected from the group of dectin-1, mannose receptor, mannan-binding lectin, complement receptor 3, complement receptor 4, and scavenger receptor class A ligand. The large number of these phagocytosis-stimulating ligands allows the possibility of selecting the most suitable molecules with regard to penetration into the tumor environment and with regard to fixation to the surface of the tumor cells. In another non-illustrated embodiment, the drug combination consists of at least one glutamine metabolism inhibitor selected from the group azaserine, 5-diazo-4-oxo-L-norvaline, acivicin, azotomycin, bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethylsulfide, ebselen, chererythrine, apomorphine, 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide. The range of glutamine metabolism inhibitors considered allows the identification of substances with a wide therapeutic window, i.e. the differentiation between therapeutically optimal concentrations and those that cause side effects.
[0028] material Tissue culture media, media supplements, mannan from Saccharomyces cerevisiae, lipoteichoic acid (LTA) from Bacillus subtilis, and sodium salt of polyinosinic:polycytidylic acid (poly(I:C)) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Resiquimod (R-848) was supplied by Tocris Bioscience (Bristol, UK). Biocompatible cell membrane anchor (BAM, Mw4000) was obtained from NOF EUROPE (Globbendonk, Belgium). Anti-CD40 monoclonal antibody (rat IgG2a, clone PGK4.5 / PGK45) was supplied by BioXCell (West Lebanon, NH, USA). 6-Diazo-5-oxo-L-norleucine (DON) was obtained from the Institute of Organic Chemistry and Biochemistry (UOCHB) in Prague, but can also be purchased commercially.
[0029] Cell lines and mice The mouse pancreatic adenocarcinoma line Panc02 was kindly provided by Prof. Lars-Ivo Partek (Greifswald, Germany). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum and antibiotics (PAA, Pasching, Austria). Cells were cultured at 37°C in a water vapor-saturated atmosphere containing 5% carbon dioxide.
[0030] Specific pathogen-free C57BL / 6 female mice (also referred to as SPF C57BL / 6 mice (female)) were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice weighing 18–20 g were housed in a specific pathogen-free environmental barrier facility and had free access to sterile food and water. The photoperiod was 12 h light / 12 h dark.
[0031] Synthesis of mannan-BAM The synthesis of mannan-BAM was carried out as previously described (Non-Patent Document 4).
[0032] Tumor implantation Subcutaneous implantation: Mice were implanted with 4 × 10 5Panc02 cells or 4 x 10 in 0.1 mL of RPMI 1640 medium 5 B16-F10 cells were injected subcutaneously without additives into the pre-shaved groin area (right or both).
[0033] Intracranial transplantation: Mice were anesthetized with an intraperitoneal injection of a mixture of ketamine (Narkamon, Bioveta, Czech Republic, 100 mg / kg) and xylazine (Rometar, Bioveta, Czech Republic, 5 mg / kg). 5 Panc02 cells were injected intracranially into mice.
[0034] Treatment and Evaluation MBTA immunotherapy: 50 μL of treatment mixture consisting of 0.5 mg R-848 (HCl form) + 0.5 mg poly(I:C), 0.5 mg LTA, and 0.4 mg anti-CD40 per mL of 0.2 mM mannan-BAM in PBS was administered intratumorally on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. Hereafter, the combination of R-848, poly(I:C), LTA, mannan-BAM, and anti-CD40 antibodies is referred to as "MBTA". For the bilateral Panc02 tumor model, MBTA therapy was always injected only into the subcutaneous tumor on the right side.
[0035] DON metabolic intervention: 100 μL of DON solution (4 mg DON per mL of phosphate buffered saline, or PBS) was administered intraperitoneally (ip) as described below. In Example 3, 200 μL of DON solution (4 mg DON / 1 mL PBS) was also administered subcutaneously (sc). Additionally, intratumoral (it) administration was investigated at the doses and schedules described below, as outlined in the Examples.
[0036] Therapeutic vaccine: For the Panc02-MBTA vaccine, Panc02 cells were resuspended in DMEM medium containing non-heat-inactivated fetal bovine serum and 0.02 mM mannan-BAM. After 2 hours of incubation at 37°C, Panc02 cells were washed and resuspended in a therapeutic mixture consisting of 0.5 mg R-848 (HCl form), 0.5 mg poly(I:C), 0.5 mg LTA, and 0.4 mg anti-CD40 per mL of 0.2 mM mannan-BAM in PBS (4 × 10 per mL of therapeutic mixture). 6 For the Panc02-PBS vaccine, Panc02 cells were resuspended in PBS (4 × 10 per mL of PBS). 6 Panc02 cells). Panc02 cells for Panc02-MBTA and Panc02-PBS vaccines were subsequently killed by freeze-thaw cycles and cell viability was determined by vital staining. 50 μL of vaccine was pulsed subcutaneously (sc) on the pre-shaved lower back (right flank) on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26.
[0037] Treatment evaluation: Tumor size was measured every other day using digital calipers. The formula V = (π / 6)AB 2 (A is the maximum tumor size, B is the minimum tumor size) to calculate tumor volume.
[0038] Flow cytometric analysis of tumor-infiltrating leukocytes Analysis of tumor-infiltrating leukocytes was performed as described in Non-Patent Document 5. Briefly, tumors were digested with Liberase DL and Dnase I (both Roche Diagnostics, Germany). The following monoclonal antibodies (eBioscience, San Diego, CA, USA) were used: a) total leukocytes - anti-mouse CD45 PerCP-Cy5.5, clone 30-F11; b) T lymphocytes - anti-mouse CD3e FITC, clone 145-2C11; c) CD4+ T lymphocytes - anti-mouse CD4 APC, clone GK1.5; d) CD8+ T lymphocytes - anti-mouse CD8a, clone 53-6.7; e) B lymphocytes - anti-mouse CD19 APC, clone eBio1D3; f) NK cells - anti-mouse NK1.1PE, clone PK136; g) granulocytes - anti-mouse Gr-1 Alexa Fluor700, clone RB68C5; h) macrophages - anti-mouse F4 / 80 antigen PE-Cy7, clone BM8. Analyses were performed using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) and BD FACSDiva software 6.1.3. (BD Biosciences, San Jose, CA, USA).
[0039] statistical analysis Tumor growth was evaluated by calculating the area under the curve (AUC). The values obtained were statistically evaluated by one-way analysis of variance with an unequal post hoc test. Kaplan-Meier survival curves were evaluated using the log-rank test. STATISTICA12 software (StatSoft, Inc., Tulsa, Oklahoma, USA) was used for all statistical evaluations. Error bars represent standard error of the mean (SEM). EXAMPLES
[0040] Synergistic effect of MBTA immunotherapy and inhibition of glutamine metabolism by DON in a mouse model of pancreatic adenocarcinoma (Panc02) with two tumors The drug combination was tested for the treatment of pancreatic adenocarcinoma, considered to be one of the deadliest tumor diseases. Mice with two advanced tumors were treated with intratumoral administration of MBTA in one of the tumors (on the right side) and with a simultaneous intraperitoneal administration of an inhibitor of glutamine metabolism, in this case 6-diazo-5-oxo-norleucine (DON).
[0041] C57BL / 6 mice were cultured with 4 × 10 5 Mouse pancreatic adenocarcinoma cells, Panc02, were subcutaneously inoculated into the shaved sites of the left and right groin. Fourteen days after tumor cell implantation, the mean volume of the primary tumor was 100.7 ± 42.1 mm. 3 , distant tumor was 104.8±43.2mm 3 At this time, mice were randomized into groups of 6 and treatment was started immediately: MBTA mixture (50 μL MBTA mixture: 0.5 mg R-848 + 0.5 mg poly(I:C) + 0.5 mg LTA + 0.4 mg anti-CD40 / mL 0.2 mM mannan-BAM in PBS) (control: PBS) was pulsed into the right tumor (days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, 26); DON (4 mg DON / mL in 100 μL PBS) (control: PBS) was administered intraperitoneally on days 5, 13, 21, 29, and 37.
[0042] The immunometabolic combination of MBTA and DON showed synergistic effects in both suppressing tumor growth (Figure 1A, B) and prolonging mouse survival (Figure 1C), whereas no mice in the other groups remained tumor-free. This experiment was performed twice with comparable results.
[0043] Fig. 1A,B: Left and right tumor growth. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test to calculate AUC (area under the curve) values. *=p<0.05, **=p<0.01. Fig. 1C: Survival analysis, log-rank test, *=p<0.05. EXAMPLES
[0044] Synergistic effect of MBTA immunotherapy and inhibition of glutamine metabolism by DON in highly advanced pancreatic adenocarcinoma (Panc02), mouse model The drug combination was tested for the treatment of very advanced pancreatic adenocarcinoma.
[0045] C57BL / 6 mice were cultured with 4 × 10 5 Mouse pancreatic adenocarcinoma cells, Panc02, were subcutaneously inoculated into the shaved site of the right groin. Twenty days after tumor cell inoculation, the tumors had grown (140.8 ± 46.8 mm 3 , Range: 37.4~247.0mm 3 At 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26, mice were randomized into groups of 6 and the appropriate treatment was started immediately. MBTA mixture (50 μL of MBTA mixture: 0.5 mg R-848 + 0.5 mg poly(I:C) + 0.5 mg LTA + 0.4 mg anti-CD40 / mL 0.2 mM mannan-BAM in PBS) (control: PBS) was pulsed intratumorally (days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26). DON (4 mg DON / mL in 100 μL of PBS) was administered intraperitoneally on days 0, 7, 14, 21, and 28.
[0046] Tumor growth inhibition was comparable in mice treated with MBTA alone and in mice treated with MBTA plus DON (Figure 2A). However, only one mouse (1 / 6) treated with MBTA alone remained tumor-free, whereas mice treated with MBTA plus DON had improved survival (3 / 6) (Figure 2B).
[0047] In addition, the three surviving mice in the MBTA / DON group were subsequently treated with 1 × 10 5Panc02 cells were intracranially injected into the 3 mice (intracranial injection was performed 174 days after the initial inoculation of Panc02 cells). All 3 mice were completely resistant to this reimplantation. Meanwhile, all mice (n = 8) in the control group died 11–14 days after intracranial Panc02 implantation (data not shown). The resistance to intracranial tumor implantation demonstrated the ability of this combination therapy to induce long-lasting systemic immune memory even in immune-privileged sites such as the central nervous system.
[0048] Figure 2A: Tumor growth. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test to calculate AUC (area under the curve) values. **=p<0.01. Figure 1B: Survival analysis, log-rank test, *=p<0.05, **=p<0.01. EXAMPLES
[0049] Synergistic effect of MBTA immunotherapy and inhibition of glutamine metabolism by DON - Pancreatic adenocarcinoma (Panc02), mouse model, vaccination The drug combination was tested for the treatment of pancreatic adenocarcinoma. Mice bearing progressive tumors on the left side were injected subcutaneously (right flank) with a suspension of dead Panc02 cells in MBTA, and simultaneously administered intraperitoneally / subcutaneously the glutamine metabolism inhibitor DON.
[0050] C57BL / 6 mice were cultured with 4 × 10 5Mouse pancreatic adenocarcinoma cells Panc02 were inoculated subcutaneously at the shaved site in the left groin. 14 days after tumor cell implantation, mice were randomly divided into groups of 6 and appropriate treatments were started immediately. A suspension of frozen Panc02 cells in MBTA (50 μL MBTA / PBS suspension: 4 mil Panc02 dead cells + 0.5 mg R-848 + 0.5 mg poly(I:C) + 0.5 mg LTA + 0.4 mg anti-CD40 / mL 0.2 mM mannan-BAM in PBS) (control: PBS) was pulsed subcutaneously at the shaved site in the right groin (days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, 26). DON was administered intraperitoneally (ip) (4 mg DON / mL in 100 μL of PBS) and subcutaneously (sc) (4 mg DON / mL in 200 μL of PBS) on days 5, 13, 21, 29, and 37.
[0051] The drug combination of MBTA and DON showed a synergistic effect in suppressing tumor growth (Figure 3A), and subcutaneous administration of DON also showed a synergistic effect in extending the survival time of mice (Figure 3B).
[0052] Figure 3A: Tumor growth. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test to calculate AUC (area under the curve) values. *=p<0.05, ****=p<0.001, *****=p<0.0005. Figure 3B: Survival analysis, log-rank test, *=p<0.05. EXAMPLES
[0053] Combination of intratumoral MBTA therapy and ip administration of a glutamine antagonist (DON) at two time points in a bilateral Panc02 model To improve the therapeutic outcome of MBTA / DON combination therapy, we tested the combination of intraperitoneal administration of DON and intratumoral MBTA therapy. A total dose of DON (2 mg / mouse / treatment) was administered in two different treatment regimens as described below.
[0054] C57BL / 6 mice were inoculated sc with Panc02 cells into both the left and right flanks. After 12 days, mice were randomized into 4 groups (n=6 / group): right tumor treated with PBS, right tumor treated with MBTA, right tumor treated with MBTA and DON ip (13 doses), and right tumor treated with MBTA and DON ip (5 doses, red). MBTA (control: PBS) was pulsed on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. DON was ip administered on days 5, 13, 21, 29, and 37 (400 μg) and on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 (154 μg).
[0055] As shown in Figure 4A, B, both treatment regimens with DON administration showed similar effects in suppressing tumor growth. The extension of mouse survival time (Figure 4C) was evident in both treatment regimens, but was not statistically significant. However, the second treatment regimen (DON administered every other day) proved to be too aggressive, leading to early death of three mice.
[0056] Fig. 4A,B: Left and right tumor growth. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test to calculate AUC (area under the curve) values. (*p<0.05, ****p<0.001, *****p<0.0005), Fig. 4C: Survival analysis. EXAMPLES
[0057] Sc administration of DON at different doses in the bilateral Panc02 model The combination of subcutaneous administration of DON and intratumoral MBTA therapy was tested. Two concentrations of DON were tested. In the first treatment regimen, the same amount of DON (2 mg / mouse / treatment) as in Example 4 was subcutaneously injected five times in parallel with MBTA therapy (400 μg / mouse / injection). In the second treatment regimen, a lower dose (80 μg / mouse / injection) was administered at the same timing.
[0058] C57BL / 6 mice were inoculated sc with Panc02 cells into both the left and right flanks. After 12 days, mice were randomized into 4 groups (n=6 / group): right tumors received PBS, right tumors received MBTA, right tumors received MBTA and low dose DON sc, and right tumors received MBTA and high dose DON sc. MBTA (control: PBS) was pulsed on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. DON (80 μg and 400 μg doses, respectively) was administered sc on days 1, 9, 17, 25, and 33.
[0059] As shown in Figures 5A and 5B, the inhibition of tumor growth was less evident compared to ip administration of DON (Example 4, Figures 4A and 4B), and no early death was observed in treated mice (Figure 5C).
[0060] Figure 5A,B: Left and right tumor growth. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test to calculate AUC (area under the curve) values (*p<0.05, *****p<0.0005), Figure 5C: Survival curve analysis (*p<0.05). EXAMPLES
[0061] Comparison of it and ip administration of DON in the bilateral Panc02 model Two treatment regimens were compared: first, injection of DON into distal MBTA-untreated tumors, and second, intraperitoneal administration of DON.
[0062] C57BL / 6 mice were inoculated sc with Panc02 cells into both the left and right flanks. Twelve days later, mice were randomized into four groups (n=6 / group): right tumors received PBS, right tumors received MBTA, right tumors received MBTA and left tumors received DON, and right tumors received MBTA and DON ip. MBTA (control: PBS) was pulsed on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. DON (400 μg) was administered it or ip on days 1, 8, 15, 22, and 29.
[0063] Intratumoral administration of DON did not improve the therapeutic effect, in contrast to ip administration, which significantly extended the survival time of treated mice (Figures 6A, B, C).
[0064] Figure 6A,B: Left and right tumor growth. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test to calculate AUC (area under the curve) values (**p<0.01, Kruskal-Wallis test), Figure 6C: Survival curve analysis (*p<0.05). EXAMPLES
[0065] Combining MBTA immunotherapy with inhibition of glutamine metabolism by DON in a bilateral Panc02 model - Evaluation of side effects Examples 4 to 6 show that the optimal method of administration of DON is ip administration with sufficient intervals between each administration. Although no early deaths were observed in treated mice with this treatment regimen, we wanted to confirm that this administration would not affect the health status of treated mice.
[0066] C57BL / 6 mice were inoculated sc with Panc02 cells into both the left and right flanks. Twelve days later, mice were randomized into three groups (n=6 / group): one group received PBS in the right tumor, one group received MBTA in the right tumor, and one group received MBTA in the right tumor plus DON ip. MBTA (control group: PBS) was pulse-injected on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. DON (400 μg) was ip administered on days 1, 8, 15, 22, and 29.
[0067] The combination of MBTA therapy and i.p. administration of DON suppressed the growth of both tumors without affecting the water and food intake or body weight of treated mice, as shown in Figure 7D–F, and significantly extended the survival time of treated mice (Figure 7A–C).
[0068] Figure 7A,B: Left and right tumor growth. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test to calculate AUC (area under the curve) values (*p<0.05), Figure 7C: Survival curve analysis (*p<0.05), Figure 7D,E,F: Evaluation of food and water intake and body weight changes of mice during the experiment. EXAMPLES
[0069] Effect of DON on immune cell infiltration in left-sided MBTA-untreated parallel pancreatic adenocarcinoma tumors, bilateral Panc02 model While examining possible side effects of DON administration, we investigated whether DON adversely affects distal tumor invasion.
[0070] C57BL / 6 mice were inoculated sc with Panc02 cells into both the left and right flanks. After 14 days, mice were randomized into 4 groups (n=16 / group): right tumors received PBS and ip PBS, right tumors received MBTA and ip PBS, right tumors received PBS and ip DON, and right tumors received MBTA and ip DON. MBTA (control: PBS) was pulsed on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. DON (400 μg) was ip on days 5, 13, 21, and 29. Flow cytometry analysis was performed on days 7, 15, 23, and 31.
[0071] As shown in Figure 8, with one exception (granulocyte count on day 23), no significant changes were observed with the addition of DON to MBTA therapy.
[0072] Figure 8: Effect of DON administration on immune cell infiltration in left-sided MBTA-untreated parallel pancreatic adenocarcinoma tumors in a bilateral Panc02 model. [Industrial Applicability]
[0073] The pharmaceutical combination for use in the treatment of cancer according to the present invention may be used in the treatment of cancer, in particular in the treatment of solid tumours such as metastatic murine pancreatic adenocarcinoma.
Claims
1. A pharmaceutical combination of active substances for use in the treatment of cancer, comprising at least one TLR ligand, at least one compound that labels tumor cells as targets for immune cell attack, at least one anti-CD40 antibody, and further at least one glutamine metabolism inhibitor.
2. 2. The pharmaceutical combination of claim 1, wherein the TLR ligand is a substance selected from the group comprising resiquimod, polyinosinic acid in acid or salt form:polycytidylic acid, lipoteichoic acid in acid or salt form.
3. The pharmaceutical combination according to claim 1 or 2, wherein the TLR ligand is a combination of at least two substances selected from resiquimod, polyinosinic acid in acid or salt form, polycytidylic acid, lipoteichoic acid in acid or salt form.
4. 2. The pharmaceutical combination of claim 1, wherein the compound that marks tumor cells as targets for innate immune cell attack is a ligand of a cellular phagocytic receptor selected from the group consisting of ligands for Dectin-1, MR, MBL, CR3, CR4 receptors, and scavenger receptors SR-A1, SR-A2, and MARCO or Mannan-BAM.
5. The pharmaceutical combination according to any one of claims 1 to 4, wherein the compound that marks tumor cells as a target for innate immune cell attack is mannan-BAM.
6. 2. The pharmaceutical combination of claim 1, wherein the glutamine metabolism inhibitor is selected from the group comprising azaserine, 6-diazo-5-oxo-L-norleucine, 5-diazo-4-oxo-L-norvaline, acivicin, azotomycin, bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide, ebselen, chererythrine, apomorphine, 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide.
7. 7. The pharmaceutical combination of any one of claims 1 to 6, comprising resiquimod, polyinosinic acid:polycytidylic acid in free acid form or in salt form, lipoteichoic acid in free acid form or in salt form, mannan-BAM, an anti-CD40 antibody, and at least one glutamine metabolism inhibitor.
8. 7. The pharmaceutical combination of any one of claims 1 to 6, comprising resiquimod, polyinosinic acid:polycytidylic acid in free acid form or salt form, lipoteichoic acid in free acid form or salt form, mannan-BAM, an anti-CD40 antibody, and 6-diazo-5-oxo-norleucine.
9. The pharmaceutical combination according to any one of claims 1 to 8, which is administered intraperitoneally, subcutaneously or intratumorally to the tissue in which the tumor is present.
10. The pharmaceutical combination according to any one of claims 1 to 9, wherein a mixture of active substances for immunotherapy comprising at least one TLR (Toll-like receptor) ligand, at least one compound which labels tumor cells as targets for immune cell attack, and at least one anti-CD40 antibody is administered into the tumor, and at least one glutamine metabolism inhibitor is administered prior to said mixture.
11. 11. The pharmaceutical combination of claim 10, wherein a mixture of active substances consisting of resiquimod, polyinosinic acid:polycytidylic acid, lipoteichoic acid, mannan-BAM, and anti-CD40 antibody is administered intratumorally and 6-diazo-5-oxo-L-norleucine is administered intratumorally or systemically prior to said mixture.
12. 10. The pharmaceutical combination according to any one of claims 1 to 9, comprising administering a mixture of active substances for immunotherapy comprising at least one TLR (Toll-like receptor) ligand, at least one compound which marks tumor cells as targets for immune cell attack, and at least one anti-CD40 antibody into the tumor, followed by administration of at least one glutamine metabolism inhibitor.
13. 13. The pharmaceutical combination of claim 12, comprising administering a mixture of active agents consisting of resiquimod, polyinosinic acid:polycytidylic acid, lipoteichoic acid, mannan-BAM, and anti-CD40 antibody intratumorally, followed by administration of 6-diazo-5-oxo-L-norleucine intratumorally or systemically.
14. The pharmaceutical combination according to any one of claims 1 to 9, characterized in that a mixture of active substances for immunotherapy comprising at least one TLR ligand, at least one compound which marks tumor cells as targets for immune cell attack, at least one anti-CD40 antibody and at least one glutamine metabolism inhibitor are administered simultaneously.
15. The pharmaceutical combination of claim 14, comprising administering a mixture of active substances consisting of resiquimod, polyinosinic acid:polycytidylic acid, lipoteichoic acid, mannan-BAM, and anti-CD40 antibody intratumorally and simultaneously administering 6-diazo-5-oxo-L-norleucine intratumorally or systemically.
16. Use of a pharmaceutical combination according to any one of claims 1 to 15 for the treatment of cancer.
17. 17. The use of claim 16, wherein the cancer is a solid tumor.
18. 18. The use according to claim 16 or 17, wherein the cancer is pancreatic adenocarcinoma.
